Abstract:Introduction: This study examined the reproductive function and prevalence of polycystic ovary syndrome (PCOS) in women with bipolar disorder taking antimanic medications. Method: Women aged 18-45 treated for bipolar disorder and not taking steroid contraceptives were recruited to complete questionnaires about their menstrual cycle and to provide blood samples for measurement of a range of reproductive endocrine and metabolic hormone levels. Eighty women participated in completing the questionnaires and 72 of them provided blood samples. Results: Fifty-two of the 80 women (65%) reported current menstrual abnormalities, 40 of which (50%) reported one or more menstrual abnormalities that preceded the diagnosis of bipolar disorder. Fifteen women (38%) reported developing menstrual abnormalities since treatment for bipolar disorder, 14 of which developed abnormalities since treatment with valproate (p = 0.04). Of the 15 patients reporting menstrual abnormalities since starting medication, 12 (80%) reported changes in menstrual flow (heavy or prolonged bleeding) and five (33%) reported changes in cycle frequency. No significant differences were observed between women receiving or not receiving valproate in mean levels of free or total serum testosterone levels. This was true for the total sample and for the sub-group without preexisting menstrual problems. However, within the valproate group, duration of use was significantly correlated with free testosterone levels (r = 0.33, p = 0.02). Three of the 50 women (6%) taking VPA, and 0% of the 22 taking other antimanic medications, met criteria for PCOS (p = 0.20). Other reproductive and metabolic values outside the normal range across treatment groups included elevated 17 alpha-OH progesterone levels, luteinizing hormone: follicle-stimulating hormone ratios, homeostatic model assessment (HOMA) values, and low estrogen and dehydroepiandrosterone sulfate (DHEAS) levels. Preexisting menstrual abnormalities predicted higher levels of 17 alpha-OH progesterone, free testosterone, and estrone as well as development of new menstrual abnormalities. Body mass index (BMI) was significantly positively correlated with free testosterone levels and insulin resistance (HOMA) across all subjects, regardless of medication used. Conclusions: Rates of menstrual disturbances are high in women with bipolar disorder and, in many cases, precede the diagnosis and treatment for the disorder. Treatment with valproate additionally contributes significantly to the development of menstrual abnormalities and an increase in testosterone levels over time. A number of bipolar women, regardless of type of medication treatment received, have reproductive and metabolic hormonal abnormalities, yet the etiology of such abnormalities requires further study. Women with preexisting menstrual abnormalities may represent a group at risk for development of reproductive dysfunction while being treated for bipolar disorder.

Insulin Resistance In Bipolar Women: Effects Of Mood-Stabilizing Drugs

Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment

Current issues: women and bipolar disorder

Reproductive function and risk for PCOS in women treated for bipolar disorder

Insulin Resistance in Women with Recurrent Miscarriage: a Systematic Review and Meta-Analysis

Sex Difference in Effects of Typical and Atypical Antipsychotics on Glucose-Insulin Homeostasis and Lipid Metabolism in First-Episode Schizophrenia.

Prevalence and characteristics of polycystic ovarian syndrome in patients with bipolar disorder

Effects of the menstrual cycle on bipolar disorder

Prevalence of insulin resistance and its associated factors in drug-naïve patients with bipolar disorder among Han Chinese population

Evaluation of reproductive function in women treated for bipolar disorder compared to healthy controls

Effect of antipsychotics and mood stabilisers on metabolism in bipolar disorder: a network meta-analysis of randomised-controlled trials

Prevalence of Type 2 Diabetes Mellitus, Impaired Fasting Glucose, General Obesity, and Abdominal Obesity in Patients with Bipolar Disorder: A Systematic Review and Meta-Analysis.

Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents

VALPROATE, BIPOLAR DISORDER AND POLYCYSTIC OVARIAN SYNDROME

Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review

Risk of adverse pregnancy, delivery and neonatal outcomes associated with bipolar disorder and prenatal use of mood stabilizers: A population-based cohort study

Shared postulations between bipolar disorder and polycystic ovary syndrome pathologies

Indices of insulin resistance and glucotoxicity are not associated with bipolar disorder or major depressive disorder, but are differently associated with inflammatory, oxidative and nitrosative biomarkers

Striking the Balance: Bipolar Disorder in the Perinatal Period

Lithium use and bone health in women with bipolar disorder: A cross‐sectional study

Risk of Diabetes Mellitus Associated with Atypical Antipsychotic Use among Patients with Bipolar Disorder: A Retrospective, Population-Based, Case-Control Study.